{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-096047","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.952366+00:00","generated_at":"2026-05-31T06:33:21.275257+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel licenses olutasidenib to Kissei for Japan, Korea, Taiwan; $10M upfront + up to $152.5M milestones","bullets":["Rigel receives $10M upfront; eligible for up to $152.5M in development, regulatory, and commercial milestones.","Mid-twenties to low-thirties percent tiered royalty on net sales; Kissei funds all development in territory.","Forma Therapeutics (Novo Nordisk) owed $2.3M from the upfront payment under prior sublicense.","Rigel retains global rights outside Japan, Korea, Taiwan; supplies bulk drug product under separate agreement.","Kissei responsible for companion diagnostic costs in Japan; Rigel shares 50% up to $3M, creditable against milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-096047","json":"https://secwatch.observer/filing/0001104659-24-096047.json","markdown":"https://secwatch.observer/filing/0001104659-24-096047.md","text":"https://secwatch.observer/filing/0001104659-24-096047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924096047/0001104659-24-096047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924096047/tm2423224d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:33:21.275257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}